Ryan N. Henderson

Array ( [id] => 907849 [patent_doc_number] => 07332646 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2008-02-19 [patent_title] => 'Transgenic animal model for degenerative diseases of cartilage' [patent_app_type] => utility [patent_app_number] => 09/717450 [patent_app_country] => US [patent_app_date] => 2000-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 11679 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/332/07332646.pdf [firstpage_image] =>[orig_patent_app_number] => 09717450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 899213 [patent_doc_number] => 07338655 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2008-03-04 [patent_title] => 'Gene therapy using TGF-β' [patent_app_type] => utility [patent_app_number] => 09/707900 [patent_app_country] => US [patent_app_date] => 2000-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 10336 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/338/07338655.pdf [firstpage_image] =>[orig_patent_app_number] => 09707900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 334310 [patent_doc_number] => 07507722 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2009-03-24 [patent_title] => 'Intravascular delivery of nucleic acid' [patent_app_type] => utility [patent_app_number] => 09/707000 [patent_app_country] => US [patent_app_date] => 2000-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11409 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/507/07507722.pdf [firstpage_image] =>[orig_patent_app_number] => 09707000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 833532 [patent_doc_number] => 07396821 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2008-07-08 [patent_title] => 'Intravascular delivery of nucleic acid' [patent_app_type] => utility [patent_app_number] => 09/707117 [patent_app_country] => US [patent_app_date] => 2000-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11403 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/396/07396821.pdf [firstpage_image] =>[orig_patent_app_number] => 09707117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1120073 [patent_doc_number] => 06797703 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-09-28 [patent_title] => 'Gene therapy using TGF- ' [patent_app_type] => B1 [patent_app_number] => 09/702718 [patent_app_country] => US [patent_app_date] => 2000-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 9607 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/797/06797703.pdf [firstpage_image] =>[orig_patent_app_number] => 09702718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1253194 [patent_doc_number] => 06670186 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-12-30 [patent_title] => 'RNA-loaded antigen presenting cells' [patent_app_type] => B1 [patent_app_number] => 09/667319 [patent_app_country] => US [patent_app_date] => 2000-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11434 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/670/06670186.pdf [firstpage_image] =>[orig_patent_app_number] => 09667319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1550891 [patent_doc_number] => 06399588 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-06-04 [patent_title] => 'Cancer treatment method utilizing plasmids suitable for IL-2 expression' [patent_app_type] => B1 [patent_app_number] => 09/628445 [patent_app_country] => US [patent_app_date] => 2000-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 20586 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/399/06399588.pdf [firstpage_image] =>[orig_patent_app_number] => 09628445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1107441 [patent_doc_number] => 06808922 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-10-26 [patent_title] => 'Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site' [patent_app_type] => B1 [patent_app_number] => 09/508516 [patent_app_country] => US [patent_app_date] => 2000-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 30 [patent_no_of_words] => 30074 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/808/06808922.pdf [firstpage_image] =>[orig_patent_app_number] => 09508516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1528926 [patent_doc_number] => 06479729 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-11-12 [patent_title] => 'Mouse model for ocular neovascularization' [patent_app_type] => B1 [patent_app_number] => 09/587184 [patent_app_country] => US [patent_app_date] => 2000-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 43 [patent_no_of_words] => 10570 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/479/06479729.pdf [firstpage_image] =>[orig_patent_app_number] => 09587184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 716421 [patent_doc_number] => 07053200 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-05-30 [patent_title] => 'Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation' [patent_app_type] => utility [patent_app_number] => 09/980381 [patent_app_country] => US [patent_app_date] => 2000-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 32514 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/053/07053200.pdf [firstpage_image] =>[orig_patent_app_number] => 09980381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7643838 [patent_doc_number] => 06429201 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-08-06 [patent_title] => 'Method for immunization against hepatitis B' [patent_app_type] => B1 [patent_app_number] => 09/570546 [patent_app_country] => US [patent_app_date] => 2000-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 33 [patent_no_of_words] => 10802 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/429/06429201.pdf [firstpage_image] =>[orig_patent_app_number] => 09570546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4423258 [patent_doc_number] => 06225448 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-05-01 [patent_title] => '1gG /transferrin receptor fusion protein' [patent_app_type] => 1 [patent_app_number] => 9/562544 [patent_app_country] => US [patent_app_date] => 2000-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 12627 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/225/06225448.pdf [firstpage_image] =>[orig_patent_app_number] => 562544 [rel_patent_id] =>[rel_patent_doc_number] =>)